Table 1.

and clinical features of the six patients

CharacteristicsPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6
Age, yr/race/sex64/AA/M50/AA/W64/AA/M49/AA/W54/AA/W56/AA/M
PMHNoneESKD s/p DDRT, HTN, DM, CKDHTN, DM, prostate cancerHTN, HLD, CKDHTN, CKDDM, HTN, MGUS, CKD
Presenting symptomsFeverFever, fatigue, DOE, diarrheaFever, fatigue, diarrhea, coughDiarrhea, cough myalgiasSore throat, neck swellingFever, vomiting, sore throat, cough
Symptoms onset to COVID-19 Dx, d228142410
Proteinuria, g7.66.118.3a12.06110.6b
OliguriaNoNoYesNoNoYes
Baseline SCr, mg/dl1.22.511.51.74
Peak SCr, mg/dl7.25.9913.5210.462.358.82
Latest SCr, mg/dl2.54.811.21.82.344.53
Required hemodialysisNoNoYesNoNoYes
Duration of hospital stay/duration of follow-up, d16/4713/9310/4218/905/4724/65
Duration of ICU stay, d200000
Ventilator dependentNoNoNoNoNoNo
COVID-19–specific medicationsNoNoNoNoNoNo
APOL1 test on bloodG1/G2G1/G1G1/G1DeclinedDeclinedDeclined
APOL1 test on kidney biopsy tissueG1/G2G1/G0cNot doneDeclinedDeclinedDeclined
Type of kidney biopsyNativeTransplantNativeNativeNativeNative
Biopsy findingsCollapsing GN, podocytopathy, TRI protein overload tubulopathyCollapsing GN, podocytopathy, TRI, protein overload tubulopathyPodocytopathy, TRI, protein overload tubulopathyPodocytopathy, TRI, protein overload tubulopathyCollapsing GN, podocytopathy, protein overload tubulopathyPodocytopathy, protein overload tubulopathy
  • AA, recent African ancestry; M, men; W, women; s/p, status post; DDRT, deceased donor renal transplant; HTN, hypertension; DM, diabetes mellitus; HLD, hyperlipidemia; MGUS, monoclonal gammopathy of unknown significance; DOE, dyspnea on exertion; Dx, diagnosis; ICU, intensive care unit; TRI, tubuloreticular inclusion.

  • a Spot urine protein creatinine ratio (UPCR).

  • b Oliguria.

  • c Donor kidney.